Featured Research

from universities, journals, and other organizations

Mechanical bowel preps offer no clinical benefit for pancreaticoduodenectomy, study suggests

Date:
May 6, 2010
Source:
Thomas Jefferson University
Summary:
A research team has concluded MBPs offer no clinical benefit to patients undergoing a pancreaticoduodenectomy.

Mechanical bowel preparations (MBP) are commonly administered preoperatively to patients who undergo a pancreaticoduodenectomy (PD) (Whipple procedure) to treat benign and malignant tumors of the pancreas, common bile duct or duodenum. MBPs are employed as a preventative measure in gastrointestinal surgery but their effectiveness in reducing perioperative infectious complications remains unclear. Now, a research team from the Department of Surgery at Jefferson Medical College of Thomas Jefferson University has concluded MBPs offer no clinical benefit to patients undergoing a pancreaticoduodenectomy. The results are set to appear in the August 2010 edition of the journal Surgery.

The researchers performed a retrospective review in which they analyzed clinical data from 100 consecutive PDs performed on patients receiving preoperative MBP from March 2006 to April 2007, and compared them to 100 consecutive patients who received a preoperative clear liquid diet (CLD) from May 2007 to March 2008. They found that there were no significant differences between the MBP and CLD groups in the rates of pancreatic fistula, intra-abdominal abscess or wound infection. There were trends toward increased urinary tract infections and Clostridium difficile infections with the MBP group. The median length of postoperative hospital stay was seven days in each group and the 12-month survival rates were equivalent.

"Based upon these data and similar results from numerous randomized prospective trials in colon and rectal surgery, we feel that patients have improved therapeutic outcomes without MBP prior to PD and we have excluded it from our practice," said Harish Lavu, M.D., assistant professor, Department of Surgery, and lead author of the study. "Given the recent influx of national and institutional quality improvement projects, it is appropriate to define the need and efficacy of MBP for PD if it is to remain in clinical practice."

MBP has been thought of as an essential factor for avoiding infectious complications and anastomotic dehiscence, most commonly in colon surgery. This is based upon the belief that MBP reduces the volume of solid or semi-solid contents at the time of surgery, theoretically reducing bacterial load, and the risk of intraoperative enteric spillage. MBP has become a standard of care across many surgical disciplines involving the gastrointestinal tract, including foregut surgery.

PD is a complex surgical procedure of the upper gastrointestinal tract designed to treat benign and malignant disorders of the pancreas and periampullary region. The operation involves resection of the pancreatic head and uncinate process, duodenum, and intra-pancreatic portion of the common bile duct, with reconstruction via anastomotic attachments between the pancreas, biliary tree, and stomach/duodenum to the jejunum. The operation is considered a clean contaminated case, and the major causes of postoperative morbidity include pancreatic fistula, intra-abdominal abscess formation, wound infection, urinary tract infection (UTI), and delayed gastric emptying.

Several members of the Jefferson Pancreas, Biliary and Related Cancer Center in the Department of Surgery co-authored this study including: Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair; Eugene Kennedy, M.D., associate professor; and Patricia Sauter, A.C.N.P. Other co-authors included Benjamin Leiby, Ph.D., assistant professor, Department of Pharmacology & Experimental Therapeutics; Ross Mazo; Robert Stewart; Christopher Greenleaf; Dane Grenada; and Sean Crocker.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. "Mechanical bowel preps offer no clinical benefit for pancreaticoduodenectomy, study suggests." ScienceDaily. ScienceDaily, 6 May 2010. <www.sciencedaily.com/releases/2010/05/100506090931.htm>.
Thomas Jefferson University. (2010, May 6). Mechanical bowel preps offer no clinical benefit for pancreaticoduodenectomy, study suggests. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2010/05/100506090931.htm
Thomas Jefferson University. "Mechanical bowel preps offer no clinical benefit for pancreaticoduodenectomy, study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/05/100506090931.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins